Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMAG's Makena Fails Confirmatory Pre-Term Birth Study, But May Not Be Pulled From Market

Executive Summary

The company will conduct subgroup analyses to support ongoing use, but analysts believe Makena is unlikely to be pulled from the market when compounded progesterone is the only alternative therapy. Nevertheless, sales already are declining, since generics launched last year.
Advertisement

Related Content

Accelerated Approval: US FDA Defends Size Of Premarket Safety Databases, Confirmatory Endpoints
AMAG buying once-bankrupt Lumara for up to $1bn
Battered by compounders on Makena, KV seeks bankruptcy protection
US FDA steps into high-price Makena preterm birth drug controversy
KV Pharma price doubles as FDA approves first preterm birth drug

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124883

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel